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lcerative Colitis [UC] is a chronic debilitating inflammatory 
process that is usually confined to the mucosa and on occasions 
submucosa of the large bowel. It affects all age groups but is 
more common at 15-30 years and spares no sex. Typically the disease 
has relapsing-remitting course. Bloody diarrhea forms the cardinal 
clinical hallmark symptom of the disease, whereas the 
histopathological hallmark of the disease is diffuse infiltration of 
lamina propria with inflammatory cells, crypt abscesses and distortion 
of the mucosal architecture.  
Extension of the disease to the muscular layers is unusual. The small bowel is never involved 
except in backwash ileitis, whereas the rectum is affected in around 95% of cases. The disease may 
present with extra-intestinal features as ocular, oral, skin, joints, liver, biliary disease and others. 
Beside the physical disability the disease has psychological consequences and considerable 
diminution of quality of life.  The etiology of UC is obscure. Nonetheless, some postulations 
concentrating on the immune system were put foreword. One of these suggests disturbance of the 
intestinal immune system-of unknown cause- results in injury of the mucosa that predispose it to 
invasion by microorganism. On the other hand some believe that the disease is rather due to 
abnormal immune response to antigens of intestinal microorganisms1,2. It appears that the T cell 
lymphocytes play a fundamental role in the inflammatory process that characterizes the disease.  
Cigarette smokers were found to be less affected by UC, this points to the role of environmental 
factors in the pathogenesis of UC 3,4. 
 
The disease that starts at the rectum is divided 
depending on its extent in the bowel into: 
ulcerative proctitis when it is limited to the 
rectum; left-sided colitis when it ascends to 
the splenic flexure; pancolitis if it goes more 
proximally.  
Truelove and Witts classification are used to 
evaluate the severity of the disease5. Based on 
the clinical presentation the disease was 
classified into: mild when there is mild 
infrequent abdominal pain and diarrhea 
without fever or weight loss; moderate when 
the abdominal pain is not severe, the fever is 
of low grade and the anemia dose not require 
blood transfusion; when the disease 
presentation extends beyond that i.e. patient 
has a high grade fever, profuse bleeding, 
frequent loose motions and significant weight 
loss the disease will be categorized as severe.  
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Fulminant disease is a medical emergency 
that requires hospital admission and special 
care. 
It was reported that not more than 50% of 
patients with ulcerative colitis will be at 
clinical remission at any time and similar 
percentage  
have a relapse yearly6,7. To improve this 
figure some effort-comparable to that done in 
management of Crohn’s disease- has to be 
done. Nevertheless, current medical and 
surgical treatment including 
immunosuppressive drugs and the ileo-anal 
pouch procedure is relatively safe and 
effective for controlling different stages of the 
disease. Finding safer- especially on long 
term management- effective, and cheep 
treatment modality remain a challenge for 
clinicians and researchers. 
In this review highlights were put on medical 
treatment of UC with light touch on screening 
for colorectal carcinoma. Details of the 
clinical, endoscopic, histopathological 
pictures as well as the local and systemic 
U 
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complications are out of the scope of this 
article. 
 
What are the Goals of UC Treatment? 
In order to improve the quality of life and 
prevent the expected complications; induction 
and maintenance of remission together with 
close monitoring for complications and side 
effects of drugs were taken as target goals for 
treatment of UC that need be achieved. 
 
Current Treatment For Ulcerative Colitis 
To date there is no curative treatment for UC 
apart from panproctocolectomy. Effectiveness 
of current medical treatment depends on the 
proper consideration of extent of the disease 
and its severity when choosing the modality 
of treatment. It worth mentioning that clinical 
remission occurs as twice as endoscopic and 
histopathological remission in each clinical 
setting. 
Aminosalicylates: 
Aminosalicylates form the corner stone for 
management of UC. 5-aminosalicylic acid [5- 
ASA] forms the active ingredient of these 
compounds utilized for treatment of UC. Its 
desired action is supposed to be in the large 
bowel. Because of its excellent absorption and 
extensive first pass metabolism to the inactive 
compound N-Ac-5ASA some work was done 
to protect 5-ASA from absorption, and 
metabolism in the stomach and proximal 
small bowel by changing the formula to delay 
or control the release of the drug to be in the 
large bowel as in Asacol, Salofalk, Mesasal,  
Claversal, and Pentasa or add some other 
compound (pro-drug) to ‘ carry’ the active 
ingredient to its site of action as in 
sulfasalazine, olsalazine and balsalazide. It is 
important to note that there is no difference in 
colonic absorption between different formulas 
of aminosalicylates8. 
Oral 5-ASA compounds were found to be less 
effective than enemas in inducing remission 
when the disease is confined to the rectum, 
but the more proximal disease mandates their 
addition to topical enemas/ suppositories to 
ensure adequate coverage of the inflamed 
mucosa. It was reported that when both oral 
and topical aminosalicylates were combined 
together, an additive increment in total 5-ASA 
dose was achieved with consequent more 
effective response than either alone9-11. Meta-
analysis had shown that there is significant 
difference in successful withdrawal rate from 
treatment between patients taking some of 
these compounds and those on placebo. 
5-ASA is found in different forms. PH 
dependent and time-control release 5-ASA are 
released in the small bowel. When combined 
with sulfa the active ingredient will be 
released only in the large bowel. However, 
the side effects of the new compound may 
overshadow its use. The majority of the side 
effects were due to the sulfa particles12. It is 
worth mentioning that 5-ASA may have as 
well serious- though infrequent- side effects 
in almost all systems of the body including 
pneomonitis, pericarditis, nephritis, bone 
marrow suppression, pancreatitis, 
hepatitis, diarrhea and hair fall. One of the 
important side effects is colonic 
hypersensitivity which closely mimics and 
may be diagnosed as refractory UC. Newer 5-
ASA compound were shown to be much 
safer. Meta-analysis studies did not show 
differences in efficacy between different 5-
ASA containing compounds. However, 
different mucosal concentration of 5-ASA 
were detected a week after cessation of 
different formulae of the compounds. It is 
crucial to know that the mucosal 
concentration of 5-ASA was found to be 
inversely correlated to the endoscopic and 
histopathological findings. This can explain 
the differences in patency between various 
formulas of the same compound 7,13,14. With 
these modalities of treatment clinical recovery 
is expected in few days, while endoscopic and 
histopathological improvement may take 
some weeks. Although 5-ASA compounds are 
effective as inducer of recovery in UC, they 
are used mainly for maintenance of remission. 
It was reported that 75% reduction of 
colorectal cancer risk occurred in patients 
with UC whose remission was maintained 
with 5-ASA.This highlights the importance of 
long term maintenance therapy especially in 
patients with extensive disease7.  Maintenance 
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therapy may not be necessary after the first 
episode of mild localized disease15.  
Again because of frequent dosing and on 
occasions by a large number of tablet; 
inconvenience leading to noncompliance was 
found to be the major factor in reducing the 
efficacy of the these drugs16,17. 
Patients who are not refractory to these 
measures may need corticosteroids.  Although 
less effective than aminosalicylates , topical 
or systemic corticosteroids form a good 
choice for induction of remission in these 
refractory patients. Although less convenient 
to patients, topical medication give quicker 
response and need lesser doses than oral ones. 
Patient’s preference may guide the choice 
between the oral or topical modalities. 
 
Corticosteroids: 
Corticosteroids suppress inflammation at 
different points via multiple pathways 
including suppression of interleukin 
transcription, arachidonic acid metabolism 
and stimulation of apoptosis of lymphocytes 
within the intestinal wall together with 
induction of IkB that stabilizes the NFkB 
complex. 
Topical and oral corticosteroids are used in 
patients who had inadequate response or 
intolerance to 5-ASA and in patients with 
moderate or sever UC. However, apart from 
the side effects, around 40% of patients may 
not respond to corticosteroids. This mandated 
looking for other alternatives18. Oral 
prednisolone is efficient inducer of remission 
in UC. When combined with rectal 
enemas/suppositories its action will be 
augmented. About 50% of topical 
corticosteroids are absorbed and may show 
the side effects. The newer corticosteroids 
like budesonide and prednisolone 
metasulphobenzoate are less absorbable and 
so they form a better choice to conventional 
ones19,20. The majority of corticosteroids side 
effects are dose dependent and rapid tapering 
of the dose may enhance rapid relapse of the 
disease. 
Intravenous corticosteroids may be the first 
option as initial treatment for severe extensive 
UC. However, if there is no adequate 
response within 7-10 days, then immune 
modulators will be highly indicated21. 
Observational studies had shown response 
rate of 60% to 80% to IV corticosteroids, but 
this was not supported with double blinded 
placebo-controlled studies22.   
 
Immunomodulators:  
It had been estimated that circulating 
antibodies were present in around 60% of 
patients with ulcerative23. Using 
immunomodulators for treatment of the 
disease is therefore not a surprise. Because of 
their tremendous side effects, these drugs are 
not routinely used to initiate or maintain 
remission. Their main role is sparing 
corticosteroids when higher doses of the latter 
are needed or be used when there is resistance 
to corticosteroids. They may also be used for 
maintenance in patients whose remission was 
induced by cyclosporine24. Understanding the 
potential toxicity and the appropriate way for 
monitoring are imperative before prescribing 
these medicines. When given even cautiously, 
close observation for evidence of pancreatitis, 
bone marrow suppression and hepatotoxicity 
is mandatory. These toxic effects were 
reversible with withdrawal of the drugs25. 
Bone marrow suppression will indirectly 
predispose the patients to opportunistic and 
different viral infections. Life-threatening 
disseminated varicella zoster and CMV 
pneumonitis were reported26,27.  
.The beneficial   effect of azathioprine [AZA] 
in induction and maintenance of remission 
were reported, and it had been proved that this 
effect was augmented when an 
aminosalicylate was added to therapy 28. 
Thiopurine methyltransferase is an important 
enzyme for the metabolism of mercaptopurine 
[MP]. Current data show that higher levels or 
activity of this enzyme are associated with 
resistance to AZA/MP therapy. Determining 
the level and or activity of this enzyme prior 
to initiation of therapy is therefore important 
to avoid an unnecessary exposure to these 
notorious drugs. This will not ameliorate the 
need for close monitoring of patients for the 
side effects29. 
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Patients on these drugs were also susceptible 
to develop lymphoma particularly EBV-
mediated lymphoma30.   Nevertheless, this 
risk of developing extra-intestinal 
malignancies which was advocated earlier 
was not supported by following reports. Non-
melanoma skin cancer is well documented in 
these patients 31,32 . 
Cyclosporine: 
Intravenous and oral cyclosporine had shown 
an excellent effect (83%) and (63%) 
respectively in patients who are corticosteroid 
refractory. In such patient this drug plays an 
important role to bridge the patient to other 
modality of maintenance therapy 33. Some 
studies had shown no difference between IV 
corticosteroids and low or high dose 
cyclosporine. Cyclosporine side effects 
remain a concern to treating teams. 
Hypomagnesaemia, renal failure and 
opportunistic infection with reported 
mortality rate of 1%-2% are among the 
serious ones. This will definitely be 
augmented by the concomitant use of other 
immune modulators and may be good reasons 
to advocate surgery over these drugs34-36. 
Oral methotrexate: 
Initial reports on oral methotrexate for 
treatment of UC were disappointing. 
However, the small dose of the drug used in 
such patients could explain those results. 
Consequent trials using larger doses of oral or 
intramuscular methotrexate showed promising 
results regarding both induction and 
maintenance of remission. When combined 
with folic acid a tremendous reduction of 
antiproliferative side effects was seen37,38.  
 
Potential Treatments For Ulcerative 
Colitis: 
Control of symptoms, cure of the disease, 
without the sequential late complications is 
the goal of treatment of UC. To date there is 
no “ideal” drug to achieve that. A drug that 
induces effective clinical, endoscopical and 
histopathological remission which can 
maintain that without serious side effects is 
still a dream. Current drugs including 
aminosalisalates, corticosteroids, 
antimetabolites, infliximab and others have all 
failed short of achieving those goals. 
 A large number of drugs were on the horizon. 
Hopefully these drugs will pass efficacy and 
safety testing and will soon be a new 
additional option for the patients. 
 
Inflammatory cytokine inhibition: 
The role of tumour necrosis factor 
alpha(TNFα) in inflammatory bowel disease 
is well established. Drugs to modulate or 
block this effect including the mouse/human 
(chimeric) 
monoclonal antibody infliximab, the 
humanized monoclonal antibody CDP571, the 
fully human monoclonal antibody 
adalimumab, the human soluble TNF p55 
receptor , thalidomide and the MAP kinase 
inhibitor CNI-1493 are coming up rapidly39. 
Infliximab: 
Although the initial reports on Infliximab- 
which is a well established mode of treatment 
in some diseases including CD- gave 
controversial results when tried with UC40, 41.  
By binding to membrane- bound TNF 
Infliximab facilitates lysis of these cells and it 
also induces apoptosis of activated T cells42,43.  
Infliximab is given as three doses to induce 
remission and then one injection every eight 
weeks for maintenance44. Recent studies had 
proved the good clinical response to 
infliximab accompanied with significant 
mucosal healing. This adds to the benefits of 
this drug as mucosal healing was thought to 
be the most important single predictor of 
reduced risk of colonic cancer in patients with 
UC. Smaller doses of infliximab were found 
to be as effective as large doses with no 
significant differences in side effect. Close 
observation and vigorous search for serious 
infections had to be implemented as fatalities 
were reported44,45, relatively recent reports 
have clearly demonstrated the benefits of this 
drug, with significant rates of clinical and 
endoscopic remission even in severe cases of 
the disease 44,46. Nevertheless, the questions 
of when and in which patient shall the 
treatment be applied remain to be answered. 
The problem of development of antibodies 
against Infliximab has complicated the matter 
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more. Antimetabolites have to be used 
concomitantly with Infliximab to prevent the 
emergence of antibodies. In such conditions, 
it will be very difficult to estimate the real 
role played by each of Infliximab and the 
antimetabolites in remission47.   Some reports 
had demonstrated the reduced likelihood of 
going to surgery in patient who had a single 
dose of infliximab. This may advocate the use 
of this drug over other ones including 
cyclosporine, steroids and antimetabolites. 
However, more studies looking particularly 
on where to put this drug in the therapeutic 
algorithm of UC, the long term out come and 
potential complications are mandatory 46. 
Selective Leukocyte Adhesion Molecule 
Inhibitors 
The exact role played by WBCs in the 
pathogenesis of UC is debatable. 
Nevertheless, the interaction between WBCs 
and inflamed vascular wall is well known. 
Recent therapeutic trials had proved the 
significant contribution of at least some 
subsets of T lymphocytes in the pathogenesis 
of UC and the mechanisms advocating that 
were postulated48.  Complex reactions 
involving many mediators were thought of as 
possible contributors in this pathological 
process. Building on that, ‘blockers’ of those 
pathways we acceptable therapeutic options 
for the disease49, 50. 
The α4β7 integren molecules subtypes that 
are present on the cell surface of a small 
proportion of T lymphocytes were highly 
selective for the gut wall and so they direct 
the leukocytes towards that wall. Blocking 
these α4β7 molecular receptors has become 
the sites of interest to the investigators. Initial 
reports on such blockers gave promising 
results. This was supported by the good 




In animal models with colitis, Tetomilast had 
shown some efficacy and its safety was 
demonstrated before. The primilinary reports 
on this drug when used for treatment of UC 
were encouraging54, 55.  
 
Tacrolimus (Fk-506): 
This is an orally well absorbable calcineurin 
inhibitor, initially it was used for treatment of 
eczema  and later became widely used in 
transplantation medicine. It has an excellent 
tolerability and had shown efficiency in 
induction of remission in refractory UC 
similer to that of cyclosporine and infliximab 
beside being a corticosteroid sparing agent. 




Recently etanercept which specifically binds 
and blocks TNF was assessed for its efficacy 
against naturally occurring cell surface TNF 
receptors. None consistent results were 
obtained57. Natalizumab has emerged as a 
promising active drug in treatment of UC. 
Unfortunately this was downgraded by the 
serious side effects of the drug including 
leukoencephalopathy which had severely over 
shadowed its benefits58-60. Visilizumab which 
selectively and instantaneously depletes T 
lymphocytes had shown a unique potential 
capability in treating severe and steroid 
refractory UC.  Controlled trials on this agent 
are still going on. Like other T cell targeting 
agent rigorous attention has to be paid to 
opportunistic infection and lymphoma61.    
Recombinant interferon-β-1a has failed to 
show convincing activity in patients with UC. 
On the other hand enemas of epidermal 
growth factor that promote mucosal healing 
had shown promising effectiveness in patients 
with left-sided UC. Abut 83% of treated 
patients had clinical remission in two weeks 
time and had significant histopathologicl 
improvement. The long term response, 
complication and risk of cancer and 
lymphoma have to be sorted out by large 
controlled studies62,63.  
LMP-420 is a purine-based compound that 
strongly inhibits production of both TNF 
mRNA and protein. It is non-toxic to white 
blood cells or intestinal epithelium.. This give 
this compound an advantage over infliximab 
as it will not lead to lysis of the cells and 
hence it will not predispose the patient to 
reactivation or infection with tuberculosis64,65.   
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It was believed that disturbance of the normal 
bacterial flora of the bowel plays an important 
role in inflammatory bowel disease. By 
deliberate introduction of beneficial micro-
organisms to the bowel, attempts were made 
to restore the balanced flora and hence induce 
remission and possibly cure of this disturbing 
disease66.  
By producing predominately IL-2, IFNc and 
TNFa, stimulated T helper 1[Th1] cells were 
believed to play an important role in the 
pathogenesis of UC. It is found that Th 1 and 
T helper 2[Th2] down regulate each other. 
Consequently if Th 2 were promoted this will 
automatically demote Th1 and so reduce the 
pro-inflammatory factors IL-2, IFNc and 
TNFa. This phenomenon has led the 
researchers to look for clinical use of 
stimulator of Th2. One of the postulated 
stimulators of Th2 is the intestinal parasitic 
helminths. It was noted that UC is less in 
areas of high helminths prevalence. 
Nevertheless, this may be simplification of 
the matter as many other immunological 
factors have to be considered. Controlled 
studies may clarify this condition67. 
 Leukocytapheresis: 
After showing significantly higher 
effectiveness than prednisolone in the recent 
years, leukocytapheresis is emerging as an 
effective, practical, applicable, with few side 
effects and possibly as a standard treatment in 
cases of severe and refractory UC in order to 
avoid surgery18, 68.  The patients who had this 
modality of therapy showed clinical 
improvement, reduced need for 
corticosteroids and on occasions total 
withdrawal of corticosteroids18. In addition to 
reducing lymphocytes, leukocytapheresis was 
found to reduce the level of some pro-
inflammatory cytokines including TNF-α, 
Interleukin [IL]1β, IL -2, IL -8 and  
interferon-γ which are usually elevated in 
patients with UC69.  
Weight reduction 
UC is characterized by the presence of 
elevated levels of several inflammatory 
modulators including IL-1, IL-6, TNF-a, and 
C-reactive protein. These same modulators 
were elevated in obese patients. Cases that 
had clinical improvement following weight 
reduction were reported70. 
Medical treatment of Mild and Moderate 
Distal Colitis: 
Proctitis and Left sided colitis: 
Around 30% of patients with UC present with 
proctitis. Rectal bleeding and urgency in the 
absence of diarrhea indicate limited distal 
colitis where 5-ASA suppositories form the 
best modality of treatment to induce and 
maintain remission, whereas enemas and 
foams are given to more proximal disease. 
The vast majority of patients respond to 
treatment. However, 5% of patients may not 
respond even to oral or intravenous 
corticosteroid and total colectomy could be 
the solution to improve the quality of life. 
Partial colectomy is not a good choice as the 
disease will eventually recur in the remnant of 
the colon71. Relief of constipation is 
occasionally helpful in patients with proctitis 
and this may need to be targeted. On the other 
hand antidiarrheal medications do not reduce 
the frequency of motions. In fact they 
predispose the patient to toxic megacolon and 
so better be avoided72. 
When the disease extends to the distal colon, 
the patients have more frequent diarrhea. 
Without systemic symptoms, topical 5-
aminosalicylic acid (5-ASA) enemas and/or 
suppositories are effective and probably form 
the drugs of choice as initial treatment to 
induce and maintain remission in these 
patients73-75.  There are no convincing data to 
support which are the best options in cases of 
failure to induce remission by 
aminosalisaltes76.  However, in some patients 
hydrocortisone foams or enemas may form a 
reasonable alternative option, but their side 
effects occasionally jeopardize their usage. 
Budesonide is a poorly absorbed synthetic 
corticosteroid. Because of its extensive first 
pass metabolism, it has a short bioavailability 
and consequently better safety profile, thus 
favoring its usage over hydrocortisone and 
prednisolone when corticosteroids are needed. 
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 Although meta-analysis of some studies had 
shown superiority of 5-ASA enemas to 
corticosteroid enemas, the decision of which 
drug to use will partially be influenced by 
other factors including the tolerability, 
availability and cost 20,77, 78. The most 
important concern –beside the adverse 
effects- to treating physicians in topical 
treatment of UC is being inconvenient to 
many patients. This usually led to non-
compliance.  Compliance and long term 
remission are of utmost importance in this 
disease where meta-analysis data had shown 
development of colorectal cancer in 18% of 
patients with long standing [30-years] disease. 
Good persistent compliance was observed to 
reduce this risk by two folds79-81.   
Aminosalisaltes are not recommended for 
induction of remission in patients with severe 
forms of UC, not only that; even their role in 
treatment of moderately severe form of the 
disease has been doubted by relatively recent 
reports82. However, because of tolerability 
and safety they are still tried before shifting to 
corticosteroids83,84. In such patients 
corticosteroids remain to be the drugs of 
choice for induction of remission. However, a 
lot of debate is still going on regarding their 
optimal dosage, rout of administration and 
duration of treatment. This is mainly because 
of the serious side effects of these drugs. 
Moreover, it had been reported that only 30% 
of patients who had clinical remission to these 
drugs, show as well endoscopic remission and 
most of the patients will become either steroid 
dependent or need surgical intervention85. For 
these reasons clinicians started using 
corticosteroid sparing drug although the data 
supporting this practice are scanty86.  
Maintenance therapy: 
One of the essential goals of management of 
UC is maintenance of clinical remission 
indicted by the continuation of absence of 
abdominal pain, diarrhoea, bleeding, passage 
of mucopus and rectal urgency and also 
maintenance of intact mucosa on endoscopy 
with absences of ulcerations, significant 
friability, granular appearance and crypt 
abscesses. Also maintenance therapy aims to 
prevent relapse of the disease. One of the 
simple signs of rectal compliance recovery is 
the ability of the patient to pass flatus without 
soiling the underwear.  These clinical and 
histopathological remissions were found to be 
associated with reduced risk of relapse28,87.  
It is crucial to get sure of complete induction 
of remission before promoting to maintenance 
therapy. Maintenance therapy has to be 
individualized. 
The aminosalicylates and purine 
antimetabolites form the classical compounds 
used worldwide for maintenance of 
remission88. Other drugs are under trials and 
probably will be soon approved for general 
use. However, we have to underscore that 
corticosteroids are not used for maintenance 
of remission. The extent of the disease and the 
drug history of the patient in particular his 
adherence to medication and the side effects 
during induction and the finance of the patient 
have to be considered before selecting the 
drug. 
Aminosalicylates compounds are the drugs of 
choice for maintenance of remission 
regardless of the way or the drug that had 
induced the remission apart from when 
corticosteroids were used for induction of 
remission where their role remains a quiz. 
Emerging data indicate that they have a 
significant chemoprotective role against 
dysplasia and colorectal cancer89. They are 
always recommended for long term utility 
except in case of mild attack that responded 
completely to the initial therapy. The patient 
has to be aware of the importance of strict 
adherence to treatment in order to have better 
life quality and to avoid complications.  
Sulfa containing aminosalicylates e .g.  
sulfasazine , were found to be more efficient 
than other aminosalicylates compounds like 
olsalazine or mesalazine in this regard but the 
side effects-which are occasionally  dose 
related- may be alarming90.   
 
Maintenance of remission in distal colitis: 
Topical (suppositories or enemas)  
aminosalicylates are effective in patients with 
proctitis and may be used for distal colitis. 
Every third day dosing was found to maintain 
remission in around 60% of patients10. 
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Patients who are not responding to 
conventional maintenance therapy need 
special consideration. Compliance of patient 
with medication, local infection or co-existing 
disease like irritable bowel syndrome has to 
be looked for beside the search for 
development of colorectal cancer before 
labeling the condition as refractory to 
treatment. In such patients high dose of 
topical aminosalicylates- when the disease is 
confined to distal colon- in addition to oral 
aminosalicylates or antimetabolites may give 
good results in 3-6 months period87.  If the 
optimal dose of 5-ASA and 
immunomodulator failed to maintain 
remission, then infliximab or colectomy has 
to be highly considered. 
Management of mild-moderate extensive 
colitis: 
Oral aminosalicylates in addition to topical 
ones form the main stay of induction of 
remission in this group of patients where the 
response is dose related. A round 80% of 
patients show good response to high doses of 
oral aminosalicylates91. Oral corticosteroids 
with / without topical therapy are reserved for 
refractory conditions, and for patients who 
demand rapid improvement.  There is no 
consensus on the initiation dose or when and 
how to taper corticosteroids. However, doses 
between 20and 60mg of prednisolone were 
found to be effective. Higher doses will be 
overshadowed by the systemic side effects. 
Bone mass density measurement is mandatory 
in patients who are on long term 
corticosteroids in order to early detect and 
treat osteoporosis. Failure to respond to this 
remedy may necessitate the use of oral 
immune-modulators 9  Surgery will remain a 
choice for those who did not respond to these 
measures87. 
 
Maintenance of remission in mild-
moderate extensive colitis: 
Oral aminosalicylates are again the drugs of 
choice for maintenance of remission. When 
the patient did not respond to corticosteroids 
or require large dose for induction that is 
difficult to taper or was dependent on them 
for maintenance of remission; he will be 
considered to have chronic UC and such 
patients may require antimetabolitis as part of 
their maintenance treatment92.  
If the patient had two flare-ups in one year 
then failure of maintenance of therapy will be 
declared and immunomodulotory therapy or 
probiotics has to be added. Patients who 
required cyclosporine or azathiprine for 
induction of remission were found to perform 
well when put on antimetabolites as 
maintenance therapy87.  Although  patients 
who are smokers were noted to be less likely 
to develop UC, studies have failed to 
demonstrate significant beneficial  role for 
nicotine in maintenance of remission93.  
Azathioprine or 6-mercaptopurine may be 
used as corticosteroid sparing in refractory 
cases or can be continued as maintenance 
regimens if they were used to induce 
remission9. 
 
Management of sever colitis: 
Hospital admission and resuscitation are 
fundamental steps in these patients. Maximal 
dose of oral aminosalicylates, oral or 
intravenous steroids are usually tried to 
induce remission.  
Failure of clear response in 7-10 days is an 
indication for parentral immunomodulator 
including azathioprin and cyclosporine, or 
infliximab94 or colectomy as the disease will 
be considered as refractory to conventional 
therapy. A bout 40% of patients will have this 
fate so close observation and collaboration 
with expert surgeons is vital95. There are no 
data to support the benefit of continuous 
corticosteroids infusion over pulse therapy in 
such cases9.  One well designed study showed 
an excellent response in 82% of 
corticosteroids- refractory patients to 
intravenous cyclosporine33.  Addition of 
azathioprine or 6-MP to cyclosporine has 
augmented the response96.  In order to avoid 
surgery, patient with fulminant UC may need 
to have similar chance of cyclosporine 
therapy. Changing the position may help to 
evacuate air and decompress the bowel in 
these patients. Because of the risk of co-
existing infection, it is common practice to 
prescribe parentertal broad spectrum 
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antibiotics to these patients despite the lack of 
convincing supportive data. This also holds 
true for total parenteral nutrition97-99. After 
induction of remission in such patients they 
will be subjected to maintenance therapy 
regimens similar o that used moderate 
extensive colitis. 
Surgery is invariably indicated in cases of 
massive or continuous hemorrhage, 
perforation and if there is cancer. Patients 
with severe refractory colitis with or without 
toxic megacolon, and those with disabling 
symptom even in less severe conditions may 
also be candidates for surgery9.  
 
Colectomy: 
Colectomy may be the ultimate fate in 9% of 
patients within the first five years of diagnosis 
of UC. This figure will increase to 35% in 
patients with pancolitis mainly because of 
failure of medical therapy100.  
Creation of ileoanal pouch following 
colectomy has greatly popularized surgery, as 
it has ameliorated the inconvenience of 
ileostomy/ colostomy. However, pouchitis 
developing in 50%, pouch failure in 10%, 
reduction of female fertility by 80% and 
nocturnal fecal incontinence in 24% of 
patients are a major concern and challenge to 
treating team101-104.  
 
Surveillance for Colonic Carcinoma in UC: 
Colorectal cancer (CRC) is a well recognized 
complication of UC. One of the goals of 
management of UC is to avoid or treat CRC if 
it developed in these patients. The risk 
increases with the duration and extent of the 
disease. It is curable when detected early and 
this highlights the importance of early 
detection. Therefore screening of CRC is of 
utmost importance to achieve this goal. 
Several methods do exist for screening 
including fecal occult blood tests and 
radiological screening with barium enema or 
CT colonography. Sigmoidoscopy and or 
colonoscopy although semi-invasive are of 
particular importance as they allow for tissue 
diagnosis of suspected lesions105.  Only 
57.3% of the patients with UC had screening 
for CRC indicating underutilization of these 
screening methods.  Patients’ awareness, 
availability, possible complications and cost 
of these tests markedly influence the rate of 
screening106. The initial reports of increased 
risk of lymphoma in patients with UC were 
contrasted with recent researches. This had 
strongly pointed to the medications used in 




Relapses of the disease are common. 
Exclusion of other causes of bloody diarrhea 
has to be made before diagnosing relapse. 
Pathogens are present in a high percentage 
[50%] of patients with UC who had relapse of 
the disease. Investigating stool by culture is 
therefore important to avoid unnecessary 
delay in managing these patients72.  
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